Big credit to the MRD2STOP trial for work with deescalation of myeloma maintenance therapy depending on MRD status. Saved patients $21M in drugs over 3 years!! We need more of this! #ASCO24

#ASH24 Impressive real-world data from the Greek myeloma group suggesting that sustained MRD negativity for 3 years can guide discontinuation of lenalidomide maintenance, probably except in patients with +2 high risk cytogenetics. #mmsm Thanos Dimopoulos

Nikhil C. Munshi, MD giving a state of art talk on MRD at the International Myeloma Society educational workshop in Johannesburg is S Africa 👏Noopur Raje

🎯 Is your MRD test really seeing the marrow? Bone marrow-based MRD assays rely on bone marrow aspirate pulls taken after several mL have already been sent for morphology, FISH, and other labs. By that point? Plasma cell content drops and hemodilution can become a major

We’re walking and matching for Myeloma Canada ! 🩸 On September 28, our team is stepping up for the Multiple Myeloma March to raise critical funds for Myeloma Canada. Why it matters: Through Myeloma Canada your donation helps: - Fund clinical research that turns discoveries

Myeloma: a sky full of MRD stars ow.ly/71lA50WBCAC #clinicaltrialsandobservations

Bone marrow tests might not be forever. Blood testing is on the rise. 🩸 Dr. Durie, Chairman Emeritus of International Myeloma Foundation , dives into a major question patients often ask: “Can blood testing replace bone marrow testing in multiple myeloma?” The answer: It’s coming. Bone marrow

Blood-Based MRD That Keeps Up With Flow A recent study from a Czech research group shows how flow cytometry-based MRD testing at 10⁻⁵ stratifies patient outcomes in Multiple Myeloma. But how does this compare to blood-based MRD testing with EasyM? While not a perfect

📢Calling all Multiple Myeloma Specialists and Hematologists: In your experience, when managing multiple myeloma, when does MRD testing offer the most critical insight? We’d love to hear where you hope MRD will make the biggest clinical impact in the coming years. 👇 Vote and

Super excited for this!!!

Help us reach our fundraising goal for Myeloma Canada ! 🩸 We’re walking on September 28 for the Multiple Myeloma March. 💥 On September 26 at 2 p.m. ET, all donations will be MATCHED by us. That means your impact on Myeloma patients is doubled. Every dollar gets us closer to:

What is Mass Spectrometry and why does it matter for myeloma patients? Myeloma expert Dr. Brian G.M. Durie from International Myeloma Foundation explains that mass spectrometry is a highly accurate test that can measure myeloma protein levels in blood and urine more precisely than current standard

Quadruplets are now standard upfront for transplant patients, dual maintenance is expanding, MRD is guiding transplant needs, and high-risk patients benefit from continuous aggressive therapy. #AsktheIMF Joseph Mikhael

MRD Insights from the CASSIOPEIA Trial 📢 A new analysis from the landmark CASSIOPEIA study confirms what many myeloma experts have been saying: Deeper, longer lasting MRD negativity = longer progression free survival (PFS) Key Findings: - Adding daratumumab to induction,